glp-1 trial services 3 Takeaways from the Landmark Oral 'Switch' for Obesity Care GLP Agonist Clinical Trial Pipeline
Description
Diabetes Care, 43(8), 18131821
Thus, in SUSTAIN 6, a sustained, dose-related and highly significant reduction of systolic blood pressure by 5.4 mmHg relative to baseline (135 mmHg) was seen
These are not interchangeable categories, and awareness of that difference helps set appropriate expectations
Farah LXS, Valentini V, Pessoa TD et al
Side effects and safety considerations GLP-1 Complete carries a relatively benign safety profile compared to pharmaceutical alternatives
